Clinical trials in Brescia – page 16

554 clinical trials in Brescia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Brescia at a glance

554

clinical trials

Research sites2

Quick filters

554 trials in Brescia

Open in trial search

Prophylaxis of nausea and vomiting

Recruiting

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Atezolizumab
Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Contact Research Centre

Hormone-dependent prostate cancer+1

Recruiting

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Study on Lutetium (177Lu) Vipivotide Tetraxetan to Delay Recurrence in Adult Men with PSMA-Positive Oligometastatic Prostate Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Gozetotide
Sponsor:Novartis Pharma AG

Contact Research Centre

Hodgkin's disease

Recruiting

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

Registered drugNo placebo

Study on the Effectiveness and Safety of Tislelizumab for Patients with Newly Diagnosed Hodgkin Lymphoma Who Cannot Have Standard Chemotherapy

Registered drugNo placebo

Italy

Participants:65+ years
Substances:Tislelizumab
Sponsor:Fondazione Italiana Linfomi Ets

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug

Study on the Effectiveness and Safety of Dapirolizumab Pegol for Patients with Moderate to Severe Systemic Lupus Erythematosus

Registered drug

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Caffeine
Sponsor:UCB Biopharma

Contact Research Centre

Systemic lupus erythematosus

Recruiting

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Study on the Long-Term Safety of Dapirolizumab Pegol for Patients with Systemic Lupus Erythematosus

Registered drugNo placebo

Italy

Participants:0–17 years · 18–64 years · 65+ years
Substances:Anhydrous Caffeine
Sponsor:UCB Biopharma

Contact Research Centre

Chronic cutaneous lupus erythematosus+2

Recruiting

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo

Study on Long-Term Safety and Efficacy of Litifilimab for Adults with Active Subacute or Chronic Cutaneous Lupus Erythematosus Resistant to Antimalarial Therapy

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Litifilimab
Sponsor:Biogen Idec Research Limited

Contact Research Centre

Schizoaffective disorder+2

Recruiting

Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

Registered drugNo placebo

Study on the Effect of Clozapine and Drug Combination for Patients with Schizophrenia Experiencing First-Line Treatment Failure

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Amisulpride
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Bipolar disorder

Recruiting

Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

Registered drugNo placebo

Study on the Effect of Citalopram, Sertraline, and Lithium for Patients with Bipolar Depression After First-Line Treatment Failure

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Citalopram
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Acute myeloid leukaemia

Recruiting

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cytarabine
Sponsor:Fondazione Gimema Franco Mandelli Onlus

Contact Research Centre

Major depression

Recruiting

Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

Registered drugNo placebo

Study on the Effect of Ketamine and Esketamine in Patients with Major Depressive Disorder After First-Line Treatment Failure

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Agomelatine
Sponsor:Universitair Medisch Centrum Utrecht

Contact Research Centre

Gastrooesophageal cancer+1

Recruiting

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo

Study on Trastuzumab Deruxtecan and Fluorouracil for Patients with HER2-Positive Gastric or Gastroesophageal Cancer with Minimal Residual Disease

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Anhydrous Docetaxel
Sponsor:Fondazione GONO G.I.

Contact Research Centre

Chronic inflammatory demyelinating polyradiculoneuropathy

Recruiting

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Efgartigimod Alfa
Sponsor:Argenx

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 234 cities in Italy

Clinical research in Brescia

What the registry says about research in the country

01 Oncology Research

Innovative trials focusing on metastatic colorectal cancer, chronic myeloid leukemia, and renal cell carcinoma. Studies evaluate novel combination therapies and treatment strategies for advanced cancer cases.

Colorectal Cancer Treatment
Leukemia Therapies
Advanced Renal Cancer

Research includes evaluation of targeted therapies and immunotherapy approaches.

02 Neurological Disorders

Comprehensive studies addressing Parkinson's disease, Frontotemporal Dementia, and Alzheimer's-related psychosis. Research focuses on novel therapeutic approaches and disease-modifying treatments.

Early-Stage Parkinson's Treatment
Dementia Management
Neurological Drug Development

Trials aim to improve patient outcomes and quality of life.

03 Autoimmune Conditions

Groundbreaking research in Psoriatic Arthritis, Crohn's Disease, and Sjögren's Syndrome. Studies evaluate biological therapies and innovative treatment approaches.

Inflammatory Disease Management
Autoimmune Response Modulation
Novel Therapeutic Approaches

Focus on developing targeted treatments for chronic conditions.

04 Cardiovascular Research

Studies addressing heart failure prevention and cardiovascular disease. Research evaluates new combination therapies and preventive approaches.

Heart Failure Prevention
Cardiovascular Risk Reduction
Therapeutic Combinations

Emphasis on preventive strategies and innovative treatments.

Back to Italy All countries